Status:

UNKNOWN

pH, Hypoxia and Haemodialysis

Lead Sponsor:

Coventry University

Collaborating Sponsors:

University Hospitals Coventry and Warwickshire NHS Trust

Conditions:

End Stage Renal Disease on Dialysis

Eligibility:

All Genders

18+ years

Brief Summary

End-stage renal disease typically requires haemodialysis to help replace kidney function. However, changes in oxygen uptake during haemodialysis have been linked to increased all-cause mortality. This...

Detailed Description

Alkalosis may explain multiple complications of HD treatment, most notably hypoxemia. Despite a strong rationale for these mechanisms, current consensus suggests ischaemia as the predominant catalyst ...

Eligibility Criteria

Inclusion

  • On haemodialysis for at least 3 months.
  • Haemodialysis 3 times per week.
  • Age 18 years or older.

Exclusion

  • Central venous catheter.
  • Planned kidney transplant during the duration of study.

Key Trial Info

Start Date :

May 1 2021

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

December 29 2021

Estimated Enrollment :

100 Patients enrolled

Trial Details

Trial ID

NCT04501159

Start Date

May 1 2021

End Date

December 29 2021

Last Update

August 30 2021

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

UHCW

Coventry, Warwickshire, United Kingdom, CV1 3LN

2

University Hospital Coventry and Warwickshire

Coventry, West Midlands, United Kingdom, CV3

pH, Hypoxia and Haemodialysis | DecenTrialz